Neurobiological Changes When Treating Depression With Electroconvulsive Therapy - a Longitudinal Observational Study

Neurobiological Changes and Clinical Outcome When Treating Depression With Electroconvulsive Therapy.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01869868

Enrollment

Registered

2013-06-05

Start date

2013-12-31

Completion date

Unknown

Last updated

2015-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

The purpose of this study is to determine functional and structural changes in brain following treatment of severe depression with electroconvulsive therapy with correlation to clinical outcome. Our hypothesis is that there are state-dependent changes in functional connectivity within specific neurocircuits systems, as well as structural plasticity changes in hippocampus, when recovering from depression.

Detailed description

The study is a prospective, within-subject, observational follow-up study in individuals with depression who receive electroconvulsive therapy (ECT)at a psychiatric clinic. We will use a consecutive sampling method and patient referred for ECT by their psychiatrist will be screened for inclusion and asked for participation. Both in - and outpatients can be included. At three occasions (before treatment, after four week and after three months) patients will be assessed with clinical ratings, cognitive tests, functional and structural magnetic resonance imaging and biomarkers for cell proliferation.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* major depressive disorder * depressive episode in bipolar disorder * age 18 - 65 years

Exclusion criteria

* alcohol- and/or drug dependence or abuse in the past 3 months * severe/life-threatening medical disease * pregnancy * type I diabetes * neurodegenerative disorder * inability to give written informed consent to participation in the study * contradiction to MRI scanning.

Design outcomes

Primary

Measure	Time frame
Measures of hippocampal volume assessed by structural MRI	Three months
fMRI BOLD resting state functional connectivity	3 month
fMRI BOLD responses during execution of emotional and reward processing tasks	3 months
Biomarkers of cell proliferation	3 months

Secondary

Measure	Time frame
Relation between neurobiological changes and clinical and cognitive outcome	Three months

Countries

Sweden

Outcome results